Effects of the SGLT2 Inhibitor Dapagliflozin on Energy Metabolism in Patients With Type 2 Diabetes: A Randomized, Double-Blind Crossover Trial

被引:40
|
作者
Op den Kamp, Yvo J. M. [1 ]
de Ligt, Marlies [1 ]
Dautzenberg, Bas [1 ]
Kornips, Esther [1 ]
Esterline, Russell [2 ]
Hesselink, Matthijs K. C. [1 ]
Hoeks, Joris [1 ]
Schrauwen-Hinderling, Vera B. [1 ,3 ]
Havekes, Bas [4 ]
Oscarsson, Jan [5 ]
Phielix, Esther [1 ]
Schrauwen, Patrick [1 ]
机构
[1] Maastricht Univ, NUTRIM Sch Nutr & Translat Res Metab, Dept Nutr & Movement Sci, Med Ctr, Maastricht, Netherlands
[2] AstraZeneca, BioPharmaceut R&D, Gaithersburg, MD USA
[3] Maastricht Univ, Radiol & Nucl Med, Med Ctr, Maastricht, Netherlands
[4] Maastricht Univ, Internal Med, Med Ctr, Maastricht, Netherlands
[5] AstraZeneca, BioPharmaceut R&D, Late Stage Dev Cardiovasc Renal & Metab, Gothenburg, Sweden
关键词
INSULIN SENSITIVITY; RESPIRATION CHAMBER; SECRETION; MEN;
D O I
10.2337/dc20-2887
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
OBJECTIVE SGTL2 inhibitors increase urinary glucose excretion and have beneficial effects on cardiovascular and renal outcomes. The underlying mechanism may involve caloric restriction-like metabolic effects due to urinary glucose loss. We investigated the effects of dapagliflozin on 24-h energy metabolism and insulin sensitivity in patients with type 2 diabetes. RESEARCH DESIGN AND METHODS There were 26 patients with type 2 diabetes randomized to a 5-week double-blind, crossover study with a 6- to 8-week washout. Indirect calorimetry was used to measure 24-h energy metabolism and the respiratory exchange ratio (RER), both by whole-room calorimetry and by ventilated hood during a two-step euglycemic-hyperinsulinemic clamp. Results are presented as the differences in least squares mean (95% CI) between treatments. RESULTS Evaluable patients (n = 24) had a mean (SD) age of 64.2 (4.6) years, BMI of 28.1 (2.4) kg/m(2), and HbA(1c) of 6.9% (0.7) (51.7 [6.8] mmol/mol). Rate of glucose disappearance was unaffected by dapagliflozin, whereas fasting endogenous glucose production (EGP) increased by dapagliflozin (+2.27 [1.39, 3.14] mu mol/kg/min, P < 0.0001). Insulin-induced suppression of EGP (-1.71 [-2.75, -0.63] mu mol/kg/min, P = 0.0036) and plasma free fatty acids (-21.93% [-39.31, -4.54], P = 0.016) was greater with dapagliflozin. Twenty-four-hour energy expenditure (-0.11 [-0.24, 0.03] MJ/day) remained unaffected by dapagliflozin, but dapagliflozin reduced the RER during daytime and nighttime, resulting in an increased day-to-nighttime difference in the RER (-0.010 [-0.017, -0.002], P = 0.016). Dapagliflozin treatment resulted in a negative 24-h energy and fat balance (-20.51 [-27.90, -13.12] g/day). CONCLUSIONS Dapagliflozin treatment for 5 weeks resulted in major adjustments of metabolism mimicking caloric restriction, increased fat oxidation, improved hepatic and adipose insulin sensitivity, and improved 24-h energy metabolism.
引用
收藏
页码:1334 / 1343
页数:10
相关论文
共 50 条
  • [31] The SGLT2 Inhibitor Dapagliflozin Reduces Liver Fat but Does Not Affect Tissue Insulin Sensitivity: A Randomized, Double-Blind, Placebo-Controlled Study With 8-Week Treatment in Type 2 Diabetes Patients
    Latva-Rasku, Aino
    Honka, Miikka-Juhani
    Kullberg, Joel
    Mononen, Nina
    Lehtimaeki, Terho
    Saltevo, Juha
    Kirjavainen, Anna K.
    Saunavaara, Virva
    Iozzo, Patricia
    Johansson, Lars
    Oscarsson, Jan
    Hannukainen, Jarna C.
    Nuutila, Pirjo
    DIABETES CARE, 2019, 42 (05) : 931 - 937
  • [32] SGLT2 Inhibitor Dapagliflozin Increases Skeletal Muscle and Brain Fatty Acid Uptake in Individuals With Type 2 Diabetes: A Randomized Double-Blind Placebo-Controlled Positron Emission Tomography Study
    Latva-Rasku, Aino
    Rebelos, Eleni
    Tuisku, Jouni
    Aarnio, Richard
    Bhowmik, Achol
    Keskinen, Helmi
    Laurila, Sanna
    Lahesmaa-Hatting, Minna
    Pekkarinen, Laura
    Isackson, Henrik
    Kirjavainen, Anna K.
    Koffert, Jukka
    Heurling, Kerstin
    Nummenmaa, Lauri
    Ferrannini, Ele
    Oldgren, Jonas
    Oscarsson, Jan
    Nuutila, Pirjo
    DIABETES CARE, 2024, 47 (09)
  • [33] Effects of 12-week treatment with dapagliflozin and gliclazide on faecal microbiome: Results of a double-blind randomized trial in patients with type 2 diabetes
    van Bommel, E. J. M.
    Herrema, H.
    Davids, M.
    Kramer, M. H. H.
    Nieuwdorp, M.
    van Raalte, D. H.
    DIABETES & METABOLISM, 2020, 46 (02) : 164 - 168
  • [34] Randomized, Double-Blind Trial of Triple Therapy With Saxagliptin Add-on to Dapagliflozin Plus Metformin in Patients With Type 2 Diabetes
    Matthaei, Stephan
    Catrinoiu, Doina
    Celinski, Aleksander
    Ekholm, Ella
    Cook, William
    Hirshberg, Boaz
    Chen, Hungta
    Iqbal, Nayyar
    Hansen, Lars
    DIABETES CARE, 2015, 38 (11) : 2018 - 2024
  • [35] The Effect of SGLT2 Inhibitor Dapagliflozin on BMI in Female Adolescents with Type 1 Diabetes
    Roman, R.
    Valdivia, N.
    Ruiz, S.
    HORMONE RESEARCH IN PAEDIATRICS, 2015, 84 : 13 - 13
  • [36] Metabolic changes induced by dapagliflozin, an SGLT2 inhibitor, in Japanese patients with type 2 diabetes treated by oral anti-diabetic agents: A randomized, clinical trial
    Horibe, Kayo
    Morino, Katsutaro
    Miyazawa, Itsuko
    Tanaka-Mizuno, Sachiko
    Kondo, Keiko
    Sato, Daisuke
    Ohashi, Natsuko
    Ida, Shogo
    Yanagimachi, Tsuyoshi
    Yoshimura, Masahiro
    Itoh, Ryuta
    Murata, Kiyoshi
    Miura, Katsuyuki
    Arima, Hisatomi
    Fujita, Yukihiro
    Ugi, Satoshi
    Maegawa, Hiroshi
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2022, 186
  • [37] SGLT2-INHIBITION IMPROVES VASCULAR FUNCTION IN TYPE 2 DIABETES: A DOUBLE BLIND, RANDOMIZED, PLACEBO CONTROLLED CROSSOVER TRIAL
    Kristensen, Didde Kidmose
    Nielsen, Steffen Flindt
    Buus, Niels Henrik
    Duus, Camilla
    Marup, Frederik
    Bech, Jesper
    Mose, Frank
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2023, 38 : I1006 - I1007
  • [38] The effect of SGLT2 inhibitor dapagliflozin on substrate metabolism in humans with prediabetes
    Veelen, A.
    Andriessen, C.
    Op den Kamp, Y.
    Tapia, E. Erazo
    de Ligt, M.
    Mevenkamp, J.
    Jorgensen, J.
    Moonen-Kornips, E.
    Schaart, G.
    Havekes, B.
    Oscarsson, J.
    Schrauwen-Hinderling, V.
    Phielix, E.
    Schrauwen, P.
    DIABETOLOGIA, 2022, 65 (SUPPL 1) : S6 - S6
  • [39] Exposure-efficacy outcome modeling for dapagliflozin, an orally selective SGLT2 inhibitor, in patients with type 2 diabetes
    Feng, Yan
    Zhang, Liping
    List, James F.
    Pfister, Marc
    JOURNAL OF CLINICAL PHARMACOLOGY, 2008, 48 (09): : 1114 - 1114
  • [40] Treatment with SGLT2 inhibitor dapagliflozin for non-alcoholic steatohepatitis patients complicated with type 2 diabetes mellitus
    Tobita, Hiroshi
    Sato, Shuiti
    Miyake, Tatuya
    Yazaki, Tomotaka
    Isoda, Kazuki
    Mishiro, Tuyoshi
    Ishihara, Shunji
    Kinoshita, Yoshikazu
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2016, 31 : 388 - 388